Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1636 1658
This examiner grants 59% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17194177 | GLP-1R AGONIST AND METHODS OF TREATMENT | Non-Final OA | The Johns Hopkins University |
| 19051398 | METHOD OF INCREASING THE FUNCTION OF AN AAV VECTOR | Non-Final OA | The Trustees of the University of Pennsylvania |
| 18000576 | FUNGICIDAL COMPOSITIONS | Final Rejection | SYNGENTA CROP PROTECTION AG |
| 18013479 | GLP-1R AGONISTIC PEPTIDES WITH REDUCED ACTIVITY | Non-Final OA | SANOFI |
| 17798868 | COMPLEX STRUCTURES FROM STIMULI-RESPONSIVE PROTEINS | Non-Final OA | Duke University |
| 18615987 | HDL-ASSOCIATED PROTEIN EXTRACTION AND DETECTION | Non-Final OA | CLEVELAND HEARTLAB, INC. |
| 18270520 | SYNTHESIS OF TEDUGLUTIDE | Non-Final OA | BIOCON LIMITED |
| 18031251 | TG2 INHIBITORS FOR IMPROVING MUCOCILIARY CLEARANCE IN RESPIRATORY DISEASES | Non-Final OA | ASSISTANCE PUBLIQUE-HÔPITAUX DE PARIS (APHP) |
| 18479600 | METHODS AND COMPOSITIONS FOR TREATING MICROBIAL INFLAMMATION | Final Rejection | THE UNITED STATES AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS |
| 18469512 | EFFECTOR PROTEINS, EFFECTOR PARTNERS, COMPOSITIONS, SYSTEMS AND METHODS OF USE THEREOF | Non-Final OA | Mammoth Biosciences, Inc. |
| 18467967 | Compositions Comprising Cas9/guide RNA Complexes for Inducing Targeted Disruption of Endogenous Genes in Eukaryotic Cells | Non-Final OA | TOOLGEN INCORPORATED |
| 18313946 | COMPOSITION FOR CLEAVING A TARGET DNA COMPRISING A GUIDE RNA SPECIFIC FOR THE TARGET DNA AND CAS PROTEIN-ENCODING NUCLEIC ACID OR CAS PROTEIN, AND USE THEREOF | Non-Final OA | TOOLGEN INCORPORATED |
| 17004355 | COMPOSITION FOR CLEAVING A TARGET DNA COMPRISING A GUIDE RNA SPECIFIC FOR THE TARGET DNA AND CAS PROTEIN-ENCODING NUCLEIC ACID OR CAS PROTEIN, AND USE THEREOF | Final Rejection | TOOLGEN INCORPORATED |
| 18247684 | USE OF PHOSPHATIDYLSERINE IN PREPARATION OF DRUG FOR TREATING INFLAMMATORY BOWEL DISEASE | Final Rejection | JIANGSU TARGET BIOMEDICAL RESEARCH INSTITUTE CO., LTD. |
| 18453936 | ANTIMICROBIAL FUSION PEPTIDES | Non-Final OA | Lundquist institute for Biomedical Innovation at Harbor-UCLA Medical Center |
| 18276724 | METHODS AND THREAPEUTIC COMBINATIONS FOR TREATING IDIOPATHIC INTRACRANIAL HYPERTENSION AND CLUSTER HEADACHES | Non-Final OA | NBO PHARMA INC. |
| 18267693 | CATH2 DERIVATIVES FOR STIMULATING INNATE IMMUNE MEMORY | Non-Final OA | Universiteit Utrecht Holding B.V. |
| 17781669 | PHARMACEUTICAL COMPOSITION COMPRISING SMALL OCTOPUS-DERIVED PEPTIDE FOR TREATMENT OF INFLAMMATORY DISEASE | Final Rejection | NATIONAL MARINE BIODIVERSITY INSTITUTE OF KOREA |
| 18248137 | TREATMENT OF DERMATOLOGICAL CONDITIONS | Non-Final OA | MC2 Therapeutics Ltd |
| 18009304 | REAGENTS AND METHODS FOR ANTIBODY SEQUENCING | Non-Final OA | RAPID NOVOR, INC. |
| 17775473 | Systems Chemico-Pharmacology Drugs and Methods of Use | Final Rejection | Reneurogen LLC |
| 17719969 | ORAL ADMINISTRATION OF UNSTABLE OR POORLY-ABSORBED DRUGS | Final Rejection | InnoPharmax, Inc. |
| 17555375 | MODIFIED RECOMBINANT HUMAN NERVE GROWTH FACTOR AND METHOD FOR PREPARING THE SAME | Final Rejection | Xintrum Pharmaceuticals, Ltd. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy